profit from every $100 of sales.
$0$100
Revelation Biosciences
$0.00+5.88% today
-71.4% in 1 year
1-year low $0.001-year high $0.01
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Revelation Biosciences sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$8.91 million of profit last year.
SalesProfit
Revelation Biosciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Revelation Biosciences | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Revelation Biosciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -11 | -9 | -8 | -9 | |
| -11 | -9 | -8 | -9 | |
| -11 | -0 | -15 | -9 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 6 | 12 | 7 | 12 |
| Cash | 5 | 12 | 6 | 11 |
| Total debt | 0 | – | 0 | 1 |
| Total liabilities | 4 | 6 | 2 | 3 |
| 1 | 7 | 5 | 9 | |
| – | – | – | – | |
| -815.5% | -102.9% | -133.8% | -74.6% | |
| -1,029.0% | -1.8% | -319.4% | -100.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -11 | -7 | -18 | -8 | |
| – | – | 0 | – | |
| -11 | -7 | -18 | -8 | |
| Dividends paid | – | – | – | – |
| – | 0 | 0 | – | |
| 0 | 0 | 0 | 1 |
Valuation
- –
- –
- –
- 0.2×
- 0.0×
- –
- 0.9×
- -7,385.8%
- -314.3%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -73.2%
- 2,609.6%
- -107.7%
- -65.6%
- -73.9%
- –
Growth
- –
- –
- +54.9%
- –
- +470.1%
Financial health
- 1.3×
- 0.06
- 5.0%
- –
- 10.02
- 10.02
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 2%of 952
Bottom 20%of 884
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -2.71 | -2.71 | +0.0% |
| Feb 26, 2026 | -1.65 | -3.66 | +54.9% |
| Nov 6, 2025 | -0.72 | -5.34 | +86.5% |
| Aug 8, 2025 | -3.05 | -2.76 | −10.3% |
| May 8, 2025 | -2.11 | -20.64 | +89.8% |
| Sep 30, 2023 | -0.42 | – | – |
| Jun 30, 2023 | -0.46 | – | – |
| Mar 31, 2023 | 4.44 | – | – |
News
Revelation Biosciences GAAP EPS of -$5.92Seeking Alpha · Nov 6, 2026OpenAI's latest AI revelation is a 'serious situation,' Microsoft's Suleyman tells CNBCCNBC · Sep 18, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
46No pass
Benjamin Graham
80Pass
Philip Fisher
41No pass
Peter Lynch
61Pass
Joel Greenblatt
52No pass
Charlie Munger
36No pass
Terry Smith
33No pass
Questions about Revelation Biosciences
Is Revelation Biosciences a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Revelation Biosciences AI analysis
What does Revelation Biosciences do?
Revelation Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunologic-based therapeutics and diagnostics for the prevention and treatment of disease. It is in Biotechnology.
Does Revelation Biosciences pay a dividend?
No. Revelation Biosciences does not pay a dividend at the moment.
How has Revelation Biosciences stock done over the past year?
Down 71.4% over the past twelve months, to $0.00. It traded between $0.00 and $0.01 and is 71.9% below its high.
Who are Revelation Biosciences's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Revelation Biosciences's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.